Bupropion as a Smoking Cessation Aid in Alcoholics
This study has been completed.
Information provided by:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First received: August 28, 2002
Last updated: January 25, 2008
Last verified: January 2008
The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.
Drug: bupropion (Wellbutrin)
Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
||Bupropion as a Smoking Cessation Aid in Alcoholics
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2005 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||25 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Currently a patient in the Omaha VA Medical Center, Substance Abuse Treatment Center (SATC) or at Catholic Charities Campus for Hope.
- Have a diagnosis of alcohol abuse or alcohol dependence.
- Smoke 20 or more cigarettes/day (may also smoke pipes/cigars).
- Be interested in quitting smoking.
- Provide name, addresses, and phone numbers of at least two individuals who can provide information on their alcohol, nicotine, and other drug use during the follow-up period.
- If female, patient must a) be of non-childbearing potential, b) have a negative pregnancy test, c) sign a document stating they do not plan on becoming pregnant during the study.
- Agree to sign informed consent.
- Able to read and understand study-related forms and procedures.
- Advanced cardiac, pulmonary, renal, or liver disease.
- History of seizures.
- History of brain tumor or significant head trauma.
- History of bulimia or anorexia nervosa.
- Current major depressive disorder or past history of panic disorders, schizophrenia, or bipolar affective disorder.
- Using psychoactive drugs.
- Receiving treatment with medications that lower seizure thresholds.
- Use of an investigational drug in any study in the past four weeks.
- Currently using any asthma medication.
- Used time-released bupropion in the past 12 months.
- Currently using any other treatments to stop smoking.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00044434
|VA/Nebraska/Western Iowa Health Care System
|Omaha, Nebraska, United States, 68105 |
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 28, 2002
||January 25, 2008
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 10, 2014
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs